FDA Warns of Risk of Using Cancer Drug for Unapproved Indication

FDA Warns of Risk of Using Cancer Drug for Unapproved Indication

The FDA is reminding both patients and doctors that the cancer drug Keytruda (pembrolizumab) is not approved for use in multiple myeloma after an unusual number of deaths in clinical trials investigating Keytruda in combination with 2 other therapies for the blood cancer.

Two trials examining Keytruda in combination with immunomodulators such as Revlimid (lenalidomide) and Pomalyst (pomalidomide) for multiple myeloma were put on hold in July after investigators reported an “excess” number of deaths in those being treated with Keytruda compared to those in a control arm that did not include the drug. At that time, researchers stopped giving Keytruda to patients in the trials.

“Today’s alert underscores the importance of why new therapies are thoroughly studied to ensure the benefits of taking them outweigh the risks to patients, and we will continue to aggressively monitor clinical trials to ensure patients are protected when safety concerns arise,” Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, said in a statement.

The FDA also said that if patients are taking Keytruda for approved uses — which include head and neck cancer, Hodgkin lymphoma and melanoma — they should continue taking the medication, as the agency believes the benefits outweigh the risks for these conditions.


Jonathan Block

Jonathan Block

Jonathan Block is a freelance writer and former MedShadow content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including BioCentury, The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Covid-19: Side Effects of Trump’s Treatments

Covid-19: Side Effects of Trump’s Treatments

President Donald Trump announced (via Twitter, of course) what some considered unthinkable, and others considered inevitable — that he had tested positive for Covid-19. Over the weekend, he received various treatments  — supplements like vitamin D, zinc and melatonin, an experimental antibody combination, an antiviral drug and a powerful anti-inflammatory…

Un-Sheltering Tips for Your Health and Immune System

Un-Sheltering Tips for Your Health and Immune System

As we all emerge from our bubbles of limited contact with others, we are walking straight into the double whammy of flu season and COVID-19 germs. Can your body fight off exposure to the flu and COVID? Your immune system feeds off the basics of life — sleep, movement, food…

  • Advertisement